NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - US67079U3068 - Common Stock
92.4 USD
-3.78 (-3.93%)
95.57 USD
+3.17 (+3.43%)
Taking everything into account, NUTX scores 6 out of 10 in our fundamental rating. NUTX was compared to 104 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of NUTX get a neutral evaluation. Nothing too spectacular is happening here. NUTX is growing strongly while it also seems undervalued. This is an interesting combination This makes NUTX very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
In the past year NUTX had a positive cash flow from operations.
In the past 5 years NUTX reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
1.2 Ratios
NUTX has a better Return On Assets (8.82%) than 92.31% of its industry peers.
NUTX has a Return On Equity of 34.08%. This is amongst the best in the industry. NUTX outperforms 95.19% of its industry peers.
With an excellent Return On Invested Capital value of 30.54%, NUTX belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX has a Profit Margin of 10.76%. This is amongst the best in the industry. NUTX outperforms 96.15% of its industry peers.
Looking at the Operating Margin, with a value of 33.39%, NUTX belongs to the top of the industry, outperforming 99.04% of the companies in the same industry.
NUTX's Gross Margin of 48.77% is fine compared to the rest of the industry. NUTX outperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NUTX is creating value.
Compared to 1 year ago, NUTX has less shares outstanding
The number of shares outstanding for NUTX has been increased compared to 5 years ago.
NUTX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.02 indicates that NUTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
NUTX has a Altman-Z score (2.02) which is comparable to the rest of the industry.
The Debt to FCF ratio of NUTX is 4.45, which is a neutral value as it means it would take NUTX, 4.45 years of fcf income to pay off all of its debts.
NUTX has a better Debt to FCF ratio (4.45) than 75.00% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that NUTX has dependencies on debt financing.
NUTX's Debt to Equity ratio of 1.46 is on the low side compared to the rest of the industry. NUTX is outperformed by 70.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.02 |
ROIC/WACC4.45
WACC6.86%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
The Current ratio of NUTX (2.27) is better than 78.85% of its industry peers.
NUTX has a Quick Ratio of 2.26. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NUTX (2.26) is better than 78.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 430.28%, which is quite impressive.
The Revenue has grown by 141.25% in the past year. This is a very strong growth!
Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
NUTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.68% yearly.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.82% yearly.
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year144.93%
Revenue Next 2Y59.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.77 indicates a rather cheap valuation of NUTX.
Based on the Price/Earnings ratio, NUTX is valued cheaper than 94.23% of the companies in the same industry.
When comparing the Price/Earnings ratio of NUTX to the average of the S&P500 Index (27.24), we can say NUTX is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.70, the valuation of NUTX can be described as very cheap.
Based on the Price/Forward Earnings ratio, NUTX is valued cheaper than 95.19% of the companies in the same industry.
NUTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.77 | ||
| Fwd PE | 6.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 99.04% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 90.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.4 | ||
| EV/EBITDA | 3.29 |
4.3 Compensation for Growth
The decent profitability rating of NUTX may justify a higher PE ratio.
A more expensive valuation may be justified as NUTX's earnings are expected to grow with 25.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
92.4
-3.78 (-3.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners21.51%
Inst Owner Change60.68%
Ins Owners3.03%
Ins Owner Change0%
Market Cap513.74M
Analysts82.22
Price Target253.3 (174.13%)
Short Float %25.35%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.23%
PT rev (3m)143.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-236.05%
EPS NY rev (1m)0%
EPS NY rev (3m)43.23%
Revenue NQ rev (1m)-5.47%
Revenue NQ rev (3m)53.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)67.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.77 | ||
| Fwd PE | 6.7 | ||
| P/S | 0.82 | ||
| P/FCF | 7.4 | ||
| P/OCF | 7.23 | ||
| P/B | 2.61 | ||
| P/tB | 3.06 | ||
| EV/EBITDA | 3.29 |
EPS(TTM)11.89
EY12.87%
EPS(NY)13.79
Fwd EY14.92%
FCF(TTM)12.49
FCFY13.52%
OCF(TTM)12.78
OCFY13.83%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.02 |
F-Score8
WACC6.86%
ROIC/WACC4.45
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year144.93%
Revenue Next 2Y59.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1011.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A